H19 and ovarian cancer: Interestingly, knockdown of lncRNA H19 in A2780/CDDP cells restored cisplatin sensitivity reducing NQO1 and NRF2 expression, proving that lncRNA H19 has a pivotal role in cisplatin resistance of ovarian cancer cells modulating NRF2/NQO1 signaling [68].